Svetlana Chulkova

Dr. Svetlana Chulkova

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2019 in Cells
Verified
Journal Article
Open access
PDF file
OCOlga Chernysheva
Olga Chernysheva
IMIrina Markina
Irina Markina
LDLev Demidov
Lev Demidov
NKNatalia Kupryshina
Natalia Kupryshina
SCSvetlana Chulkova
Svetlana Chulkova
NTNikolai Tupitsyn
Nikolai Tupitsyn
Disseminated tumor cells (DTCs) are studied as a prognostic factor in many non-hematopoietic tumors. Melanoma is one of the most aggressive tumors. Forty percent of melanoma patients develop distant metastases at five or more years after curative surgery, and frequent manifestations of melanoma without an identified primary lesion may reflect the tendency of melanoma cells to spread from indolent sites such as bone marrow (BM). The purpose of this work was to evaluate the possibility of detecting melanoma DTCs in BM based on the expression of a cytoplasmatic premelanocytic glycoprotein HMB-45 using flow cytometry, to estimate the influence of DTCs’ persistence in BM on hematopoiesis, to identify the frequency of BM involvement in patients with melanoma, and to analyze DTC subset composition in melanoma. DTCs are found in 57.4% of skin melanoma cases and in as many as 28.6% of stage I cases, which confirms the aggressive course even of localized disease. Significant differences in the groups with the presence of disseminated tumor cells (DTCs+) and the lack thereof (DTC−) are noted for blast cells, the total content of granulocyte cells, and oxyphilic normoblasts of erythroid raw cells.

1 December 2019 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SCSvetlana Chulkova
Svetlana Chulkova
DRD. A. Ryabchikov
D. A. Ryabchikov
IDI. A. Dudina
I. A. Dudina
AKA. M. Kazakov
A. M. Kazakov
AEA. V. Egorova
A. V. Egorova
NTN. N. Tupitsyn
N. N. Tupitsyn
Despite recent advances in targeted and immune therapy, 5‑year overall survival in stages III–IV of melanoma is 50 and 10–20 %, respectively. Modern melanoma biomarkers, which are used in clinical practice, are not sufficiently effective for early diagnosis and prognosis assessment. In the last decade, circulating microRNAs (miRNAs) have come to be regarded as “ideal” melanoma biomarkers. This article presents the characteristics of miRNA biogenesis, as well as provides a critical review of circulating miRNAs as promising diagnostic and prognostic melanoma biomarkers.

20 November 2023 in Life
Verified
Journal Article
Open access
PDF file
IPIlya Pustinsky
Ilya Pustinsky
ADAnton Sergeevich Dvornikov
Anton Sergeevich Dvornikov
EKEkaterina Kiva
Ekaterina Kiva
SCSvetlana Chulkova
Svetlana Chulkova
AEAngelina Egorova
Angelina Egorova
SKSergey Kalinin
Sergey Kalinin
The clinical relevance of head and neck (H&N) tumors is related to the potential disfiguration of anatomical structures (by the tumor or surgical intervention), defining patients’ individual features and emotional expression, loss or restraint of vital structures functions, and untoward socio-economic sequelae. This study is aimed to improve clinical outcomes of cryosurgery in patients with H&N basal cell skin cancer by refining the indications for cryosurgical treatment. In this study, cryosurgery was used in 234 patients with different stages of cutaneous basal cell carcinoma (BCC) of the head, including 101 patients with T1 tumors, 86—with T2, 5—T3, and 42 patients with tumors relapsing after failure of preceding various treatment modalities. Post-cryosurgery recurrence rate in patients with stage I BCC was 2.7%, with stage II tumors—5.6% and 34.9%—in patients with recurred tumors. Re-recurrence after cryoablation of recurrent tumors correlated with the tumor baseline size. The best aesthetic and long-term clinical results were documented in patients with lesions <1 cm in size with clear boundaries. Thus, cryosurgery is the method of choice for the majority of stage I basal cell carcinomas of the head. For patients with advanced and recurrent skin cancer, cryosurgery is relevant in rare cases selected according to refined indications.

1 January 2019 in Онкогинекология
Verified
Journal Article
Closed access
KTKonstantin S. Titov
Konstantin S. Titov
AKAleksey M. Kazakov
Aleksey M. Kazakov
MBMaria A. Baryshnikova
Maria A. Baryshnikova
DRDenis Anatolyevich Ryabchikov
Denis Anatolyevich Ryabchikov
SCSvetlana Chulkova
Svetlana Chulkova
DZDmitry A. Zaryanov
Dmitry A. Zaryanov
Цель исследования. Провести анализ данных современной литературы о влиянии ряда молекулярных и иммунологических факторов на прогноз при трижды негативном раке молочной железы (ТНРМЖ). Дать оценку их значимости и потенциальному практическому применению. Материал и методы. В обзор включены данные, опубликованные в ведущих зарубежных журналах за последние 10 лет. Результаты. Описано прогностическое значение экспрессии различных маркеров стволовых клеток, а также сочетаний данных маркеров на течение трижды негативного рака молочной железы. Дана оценка влияния элементов клеточного микроокружения - макрофагов и опухоль-инфильтрирующих лимфоцитов - на прогноз заболевания. Проанализирована возможность определения прогноза заболевания, учитывая комбинированную оценку представленных прогностических факторов. Заключение. Агрессивное течение и неблагоприятный прогноз при ТНРМЖ диктуют необходимость в более глубоком изучении его биологических особенностей, выявлении новых факторов прогноза заболевания. Изучение фенотипа стволовых клеток опухоли (СКО), степени выраженности и состава лимфоидной инфильтрации, макрофагального статуса опухоли позволит лучше понять биологические свойства ТНРМЖ и выработать новые подходы к прогнозированию, а в дальнейшем - к лечению данного...

11 December 2018 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SCSvetlana Chulkova
Svetlana Chulkova
ESE. N. Sholokhova
E. N. Sholokhova
NGN. V. Grishchenko
N. V. Grishchenko
DRD. A. Ryabchikov
D. A. Ryabchikov
LGL. Y. Grivtsova
L. Y. Grivtsova
ЛГЛ. Ю. Гривцова
Л. Ю. Гривцова
Introduction. B1-lymphocytes are a subpopulation of B-cells, the proportion of which in the spleen accounts for 5 % of the total number of B-cells. B1-lymphocytes predominantly secrete IgM, which plays an important role in the induction of tumor cell apoptosis. Splenec tomy for the purpose of adequate lymph node dissection in gastric cancer causes marked and prolonged immunological disorders. It primarily affects the B1a-lymphocyte subpopulation, which provides a thymus-independent immune response.Objective. To study the features of the B-cell component of immunity in patients with gastric cancer.Materials and methods. The subpopulation composition of B-lymphocytes of peripheral blood of gastric cancer patients undergoing sur gical treatment using flow cytometry (Facs Can, Lysys II and FacsCanto II programs, Facs Diva program) was analyzed. Cells were stained simultaneously with three monoclonal antibodies labeled with different fluorochromes.Results. The data obtained demonstrate a violation of the composition of B-cell subpopulations. In the group of patients with standard D2 lymph node dissection and splenectomy at the preoperative stage and three months after surgery, a significant correlation was found between the relative number of B lymphocytes (p = 0.018), CD5 + B lymphocytes (p = 0.012) and the number of CD19 + CD38 + cells (p = 0.035). In addition, after surgical treatment, the percentage of CD5 + B-lymphocytes increased significantly from 12.9 to 21.8 %, while the total number of CD19 + lymphocytes and CD19 + CD21 + cells decreased.Conclusion. In patients of the experimental group, a decrease in antibody production, weakening of both general and antitumor immunity can be observed.

12 October 2020 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
SCSvetlana Chulkova
Svetlana Chulkova
NTN. N. Tupitsyn
N. N. Tupitsyn
TDT. M. Djumanazarov
T. M. Djumanazarov
APA. D. Palladina
A. D. Palladina
NKN. A. Kupryshina
N. A. Kupryshina
PKP. V. Kononetz
P. V. Kononetz
Introduction. There is evidence that disseminated tumor cells (DOCs) in the bone marrow (BM) are precursors of subsequent distant metastases. The detection of DOCs in non-small cell lung cancer (NSCLC) will provide important information about the features of metastasis, as well as the possibilities of identifying new targets for the treatment of NSCLC.Purpose of the study is to evaluate the possibility of detection DOCs in BM and to identify the frequency of BM involvement in patients with NSCLC.Materials and methods. Morphological and immunological methods studied 62 BM samples from patients with NSCLC. DOCs analysis was performed using flow cytometry (FACSCanto II, USA, Kaluza Analysis v 2.1 software), monoclonal antibodies to CD45, cytokeratins directly labeled with various fluorochromes were used.Results. DOCs (EPCAM+CD45–) in the BM were found in 43.5 % of patients (threshold level: 1 cell per 10 million myelocaricytes). The presence of DOCs did not correlate with tumor size, lymph node status, stage of the tumor process. The highest detection rates of DOCs were observed at stages IA and IIA: 60.7 % (3/5) and 58.3 % (7/12) respectively. BM involvement in adenocarcinoma was observed in 45 % (15/33) cases, in squamous cell carcinoma – in 37 % (10/27) samples (p = 0.501). It was found that DOCs are more often detected in more differentiated tumors (p = 0.023). Significant correlations between the presence of DOCs in the BM and myelogram parameters have not been established. A decrease in the number of granulocyte germ cells was observed in 4 % of BM involvement (p = 0.036).Conclusion. The possibility of detecting DOCs in the BM of NSCLC patients has been established. BM involvement was 43.5 %. DOCs are detected even in the early stages of NSCLC. Relationship between BM involvement and the degree of tumor differentiation was found. More frequent BM involvement was observed in adenocarcinoma compared with squamous cell carcinoma of the lung.Compliance with patient rights and principles of bioethicsThe study protocol was approved by the biomedical ethics committee of N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia. All patients gave written informed consent to participate in the study.